absolutely agree Terry...
...CardioCel sales are moving much much quicker than I anticipated...management should be telling the world times over...this was an exceptionally good 4C that will be improved upon next 1/4
...for the record some time ago I posted that gross margin on sales was 90%, this figure was provided to me in an email just like others here
...just do those sums with exponential sales growth factored in quarter on quarter well in to the future
... staff costs as a percentage of sales will decrease significantly, my expectation is that management will be looking to improve their gross profit margin by either increasing the price of CardioCel and/or finding yet more cost effective ways to reduce their cost of sales...
imo...AHZ will become very profitable and cash flow positive much sooner than many expect
Quarterly, page-116
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 681 | $17.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.25 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |